Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL442345 | 0.87 | ALDH1A1 (0.40) | ALDH1A1 | |
| Ether SCHEMBL3625773 | 0.87 | ALDH1A1 (0.40) | ALDH1A1 | |
| Ether SCHEMBL10712463 | 0.87 | ALDH1A1 (0.40) | ALDH1A1 | |
| Ether SCHEMBL2428958 | 0.87 | — | — | |
| Ether SCHEMBL1070400 | 0.87 | ALDH1A1 (0.40) | ALDH1A1 | |
| Methyl Alcohol SCHEMBL28261152 | 0.79 | — | — | |
| SCHEMBL23303 | 0.79 | — | — | |
| Alcohol SCHEMBL27636334 | 0.76 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL16264308 | 0.75 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL15437113 | 0.75 | ALDH1A1 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307393-B1 | A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 | ABBOTT LAB (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8168784-B2 | Processes to make apoptosis promoters | ABBOTT LABORATORIES (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2307393-A1 | A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20090318689-A1 | Processes To Make Apoptosis Promoters | ABBOTT LABORATORIES (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009155386-A1 | A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 | ABBOTT LABORATORIES (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-0408760-B1 | NEW HYDROXYLAMINE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-03-15 | — | — | EP | disclosed |
| EP-0408760-A1 | NEW HYDROXYLAMINE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318689-A1 | Processes To Make Apoptosis Promoters | BAX, BCL2, CCAR2 | ALDH1A1 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.